Press Release Archive

(BUSINESS WIRE)--According to the World Health Organization (WHO) malaria infects approximately 250 million people per year throughout the developing world and results in a grave loss of life of at least 880,000 per year. The region most severely afflicted is Sub-Saharan Africa, but the disease is also present in Asia, Latin America, the Middle East and some parts of Europe. Pfizer recognizes the important role a pharmaceutical

(BUSINESS WIRE)--The board of directors of Pfizer Inc today declared a 16-cent second-quarter 2009 dividend on the company’s common stock, payable June 2, 2009, to shareholders of record at the close of business on May 8, 2009. The second-quarter 2009 cash dividend will be the 282nd consecutive quarterly dividend paid by Pfizer. At the company’s Annual Meeting of Shareholders, Chairman and Chief Executive

(BUSINESS WIRE)--Newly released findings from the BRIDGE survey (Bridging Gaps, Expanding Outreach – Metastatic Breast Cancer Patient Survey) found that most (78 percent) women living with metastatic breast cancer (MBC) have never participated in a clinical trial. Of these women, more than half (56 percent) were never invited to consider a clinical trial and one-third (30 percent) had not been recommended a clinical trial by their

(BUSINESS WIRE)--Pfizer Investments Netherlands B.V., an indirect wholly-owned subsidiary of Pfizer Inc, announced today that it will make a tender offer to acquire a 33.77% stake in Pfizer Limited from public shareholders at a price of Rs. 675.00 per share. Successful completion of this offer, assuming full acceptance, would raise the indirect stake of Pfizer Inc in Pfizer Limited to 75% from the current level of 41.23%. The

(BUSINESS WIRE)--Pfizer (NYSE: PFE) today announced the planned leadership and organizational structure for its research and commercial operations that will become effective when the Wyeth acquisition closes. The company will establish a unique research model designed to advance the strong scientific capabilities of both Pfizer and Wyeth (NYSE: WYE) and to support the new company’s nine diverse health care businesses. At the

(BUSINESS WIRE)--Pfizer Inc announced today that it has become the first pharmaceutical company to be accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP) for ensuring the protection of human subjects taking part in early-stage clinical trials. The AAHRPP accreditation was awarded to Pfizer’s clinical research units (CRUs) in New Haven, CT, Brussels, Belgium and Singapore, where the

(BUSINESS WIRE)--Pfizer Inc today announced the discontinuation of one of its Phase 3 studies based on statistical assessment for futility: the SUN 1107 Phase 3 study of Sutent® (sunitinib malate) in advanced breast cancer. SUN 1107 evaluated single-agent sunitinib versus single-agent capecitabine for the treatment of a broad range of patients with advanced breast cancer after failure of standard treatment. An independent Data Monitoring

(BUSINESS WIRE)--Among patients aged 65 and older with established coronary heart disease, Lipitor® (atorvastatin calcium) 80 mg significantly reduced the relative risk of a first cardiovascular event by 23 percent and provided significant reductions in the risk of subsequent second, third and fourth cardiovascular events over a period of five years compared to Lipitor 10 mg, according to data presented today at the 58th annua

(BUSINESS WIRE)--Pfizer today announced the successful completion of its offering of $13.5 billion of senior unsecured notes. The notes consist of: $1.25 billion of floating rate notes due 2011 $3.50 billion of 4.45% notes due 2012 $3.00 billion of 5.35% notes due 2015 $3.25 billion of 6.20% notes due 2019 $2.50 billion of 7.20% notes due 2039